Pfizer begins study of oral drug for prevention of COVID-19

FILE PHOTO: Pfizer logo is reflected in a drop on a syringe needle in this illustration photo

The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop an easy-to-administer antiviral pill for COVID-19. In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Kuroda vows to keep BOJ's focus on COVID-19 response amid weak inflationTOKYO: The Bank of Japan will continue to focus on cushioning the economic blow from the coronavirus pandemic, given lingering uncertainty over the outlook and subdued inflation, Governor Haruhiko Kuroda said on Monday (Sep 27). Corporate funding remains severe for retailers hit by the health crisis, Kurod
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »